Guidelines of care for the management of psoriasis and psoriatic arthritis : Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics - 24/04/13

Doi : 10.1016/j.jaad.2008.02.039

Alan Menter, MD, Chair ^a, Alice Gottlieb, MD, PhD ^b, Steven R. Feldman, MD, PhD ^c, Abby S. Van Voorhees, MD ^d, Craig L. Leonardi, MD ^e, Kenneth B. Gordon, MD ^f, Mark Lebwohl, MD ^g, John Y.M. Koo, MD ^h, Craig A. Elmets, MD ⁱ, Neil J. Korman, MD, PhD ^j, Karl R. Beutner, MD, PhD ^k, Reva Bhushan, PhD ^l,^⁎
^a Baylor University Medical Center, Dallas, Texas
^b Department of Dermatology, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts
^c Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
^d Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
^e Saint Louis University, Saint Louis, Missouri
^f Division of Dermatology, Evanston Northwestern Healthcare and Department of Dermatology, Northwestern University, Fienberg School of Medicine, Chicago, Illinois
^g Department of Dermatology, Mount Sinai School of Medicine, New York, New York
^h Department of Dermatology, University of California–San Francisco, San Francisco, California
ⁱ Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama
^j Murdough Family Center For Psoriasis, Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio
^k Anacor Pharmaceuticals Inc, Palo Alto, California
^l American Academy of Dermatology, Schaumburg, Illinois

Reprint requests: Reva Bhushan, PhD, 930 E Woodfield Rd, Schaumburg, IL 60173.

Abstract

Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this first of 5 sections of the guidelines of care for psoriasis, we discuss the classification of psoriasis; associated comorbidities including autoimmune diseases, cardiovascular risk, psychiatric/psychologic issues, and cancer risk; along with assessment tools for skin disease and quality-of-life issues. Finally, we will discuss the safety and efficacy of the biologic treatments used to treat patients with psoriasis.

	Funding sources: None.
	The authors’ conflict of interest/disclosure statements appear at the end of the article.

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL